Your browser has javascript turned off or blocked. This will lead to some parts of our website to not work properly or at all. Turn on javascript for best performance.

The browser you are using is not supported by this website. All versions of Internet Explorer are no longer supported, either by us or Microsoft (read more here: https://www.microsoft.com/en-us/microsoft-365/windows/end-of-ie-support).

Please use a modern browser to fully experience our website, such as the newest versions of Edge, Chrome, Firefox or Safari etc.

Molecular Cancer Research

Rönnstrand Group

Our research

The focus of our laboratory is to understand the molecular mechanisms of cancer, specifically acute leukemia and malignant melanoma. In particular, in acute myeloid leukemia, oncogenic mutations in the receptor tyrosine kinase FLT3 is commonly occurring and correlates with poor prognosis of patients. For this reason, several selective inhibitors of FLT3 have been developed and tried in the clinic. However, the result is disappointing. Responses are usually not strong and last only for a limited time. We are interested in identifying the mechanisms of acquired resistance to targeted inhibitors. In order to improve our understanding of acute leukemia, we are also in the process of identifying novel signal transduction proteins involved in leukemogenesis and how they are regulated by e.g. phosphorylation, how they can be linked to various biological responses etc. Identification of novel signal transduction molecules and the signal transduction networks they are involved, that are of crucial importance for transformation, will help in development of novel targeted therapies. Apart from FLT3, we are also investigating the role of other receptor tyrosine kinases in cancer, e.g. AXL and KIT.

 

Aims

  • To understand the molecular mechanisms of transformation in acute leukemia with special focus on RTKs and their downstream signaling
  • To use this knowledge to manipulate the signal transduction pathways, either by identification of novel molecules with a combination of proximity-dependent biotinylation labeling of proteins combined with mass spectrometry and identification of  their posttranslational modification, CRISPR/CAS9-mediated knockout or mutagenesis, by using transgenic mice and by employing PDX-based models of acute myeloid leukemia

 

Impact

List of Team Rönnstrand's publications

Enhanced understanding of the molecular mechanisms behind various forms of acute leukemia will improve our possibilities of targeting these signal transduction events for the benefit of patients. Increased knowledge of proteins involved in transformation, their posttranslational modification status etc will also provide us with potential tools for development of novel diagnostic tools and novel biomarkers for prediction of treatment efficacy.


Team

(name linked to profile in Lund University research portal)

Lars Rönnstrand 

Principal Investigator, Lars [dot] Ronnstrand [at] med [dot] lu [dot] se

Mehreen Ahmed

Postdoc, Mehreen [dot] Ahmed [at] med [dot] lu [dot] se

Mahafarin Maralani

Postdoc, Mahafarin [dot] Maralani [at] med [dot] lu [dot] se

Lina Al-Ashiri  

PhD student, Lina [dot] Al_Ashiri [at] med [dot] lu [dot] se

Sausan Moharram 

PhD student, Sausan [dot] Moharram [at] med [dot] lu [dot] se 

Kinjal Shah 

PhD student, Kinjal [dot] Shah [at] med [dot] lu [dot] se 

Oscar Lindblad 

Research Project Participant, Oscar [dot] Lindblad [at] med [dot] lu [dot] se 

Jianmin Sun 

Laboratory Researcher, Jianmin [dot] Sun [at] med [dot] lu [dot] se 

Kazi Uddin 

Assistant Researcher, Kazi [dot] Uddin [at] med [dot] lu [dot] se